Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM

Summary

This is an open-label, phase 1b study to evaluate different approaches for CART-EGFR-IL13Ra2 dosing and further characterize the safety, feasibility, preliminary efficacy, and pharmacokinetics of CART-EGFR-IL13Ra2 cells in patients with EGFR-amplified glioblastoma that has recurred following prior radiotherapy.

Timeline

Start

2025-12-03

Primary completion

2042-11-01

Completion

2042-11-01

Drugs

Indications